Statement: Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study.
Primary_evidence: INTERVENTION 1:    Arm I (Web-Based CPM-DA)   Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.   Internet-Based Intervention: Receive web-based CPM-DA   Survey Administration: Ancillary studies INTERVENTION 2:    Arm II (Usual Care)   Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.   Survey Administration: Ancillary studies
Secondary_evidence: INTERVENTION 1:    Nivolumab + Daratumumab (TNBC)   Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24) INTERVENTION 2:    Nivolumab + Daratumumab (NSCLC)   Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)